Improvement in Therapeutic Efficacy and Reduction in Cellular Toxicity: Introduction of a Novel Anti-PSMA-Conjugated Hybrid Antiandrogen Nanoparticle-Reference-Cited by-同舟云学术

Improvement in Therapeutic Efficacy and Reduction in Cellular Toxicity: Introduction of a Novel Anti-PSMA-Conjugated Hybrid Antiandrogen Nanoparticle

Published:2018-04-04 Issue:5 Volume:15 Page:1778-1790
ISSN:1543-8384
Container-title:Molecular Pharmaceutics
language:en
Short-container-title:Mol. Pharmaceutics

Author:

Thangavel Chellappagounder,Perepelyuk Maryna,Boopathi Ettickan,Liu Yi,Polischak Steven,Deshpande Deepak A.,Rafiq Khadija,Dicker Adam P.,Knudsen Karen E.,Shoyele Sunday A.,Den Robert B.^ORCID

Funder

National Cancer Institute

National Institute of Diabetes and Digestive and Kidney Diseases

National Heart, Lung, and Blood Institute

American Cancer Society

Prostate Cancer Foundation

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.7b01024

Reference54 articles.

1. Studies on prostatic cancer

2. A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancer

3. Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials

4. ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation;Molecular Cancer;2023-10-09

2. Functionalization of Nanosystems in Cancer Treatment;Cancer Nanotechnology;2022-12-14

3. Intravenous delivery of enzalutamide based on high drug loading multifunctional graphene oxide nanoparticles for castration-resistant prostate cancer therapy;Journal of Nanobiotechnology;2020-03-18